Amgen and AstraZeneca reported positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in adults and adolescents with symptomatic, histologically active eosinophilic esophagitis, or EoE. Administered by subcutaneous injection every four weeks, the drug produced statistically significant and clinically meaningful improvements in both co-primary endpoints and all key secondary endpoints at week 24 versus placebo, with benefits sustained through week 52 across both doses tested. EoE is a chronic immune-mediated inflammatory disease in which eosinophils accumulate in the esophageal lining, causing damage and difficulty swallowing. It affects more than 470,000 people in the U.S., where prevalence has increased fivefold since 2009. TEZSPIRE is a first-in-class human monoclonal antibody that blocks thymic stromal lymphopoietin, or TSLP, a cytokine at the top of multiple inflammatory cascades. It is approved for severe asthma in the U.S., European Union, China, Japan and more than 70 other countries, and for inadequately controlled chronic rhinosinusitis with nasal polyps in the U.S., European Union, China and Japan. EoE remains an investigational use. Amgen shares were down 1.49% at $433.80 and AstraZeneca shares were down 0.63% at $165.22 in Thursday premarket trading, according to Benzinga Pro data, while earlier market updates cited different trading points and declines. The results add support for AstraZeneca's pipeline as it targets $80 billion in annual sales by 2030, although investors remain focused on upcoming cancer-trial readouts.